Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $19.18

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.1818.

Several analysts have issued reports on BCRX shares. Cantor Fitzgerald upped their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. TD Cowen began coverage on BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective for the company. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 15th. Royal Bank Of Canada reissued an “outperform” rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Finally, Needham & Company LLC increased their price objective on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.31 on Friday. The firm has a market cap of $1.53 billion, a P/E ratio of -40.61 and a beta of 1.05. The stock has a 50 day simple moving average of $7.68 and a two-hundred day simple moving average of $8.68. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. The firm’s quarterly revenue was up 49.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.06) EPS. On average, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. Headlands Technologies LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $32,000. GAMMA Investing LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $62,000. Family Legacy Financial Solutions LLC bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $72,000. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $79,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.